Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon alpha-2b and low-dose cytosine arabinoside

被引:7
作者
Garcia-Manero, G
Talpaz, M
Giles, FJ
Cortes, J
Faderl, S
O'Brien, S
Thomas, D
Verstovsek, S
Rios, MB
Shan, J
Ferrajoli, A
Wierda, W
Kantarjian, HM
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA
关键词
chronic myelogenous leukemia; polyethylene glycol interferon; cytosine arabinoside; cytogenetic response;
D O I
10.1002/cncr.11424
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. To evaluate the activity and toxicity of weekly Schering 54301, a polyethylene glycol formulation of interferon-alpha-2b (PEG-IFN-alpha-2b), with cytosine arabinoside (ara-C) in patients with chronic myelogenous leukemia (CML). METHODS. Seventy-six patients with Philadelphia chromosome (Ph)-positive early chronic-phase CML were treated with the combination of PEG-IFN-alpha-2b and ara-C (10 mg daily,subcutaneously [s.c.]). The starting dose of PEG-IFN-alpha-2b was 6 mug/kg s.c. weekly in the first 24 patients but was reduced to 4.5 mug/kg in the next 52 patients. RESULTS. Overall, 73% of patients had a complete hematologic response, 35% of patients had a major cytogenetic response (Ph < 35%), and 21% of patients had a complete cytogenetic response (Ph = 0%). With a median follow-up of 19 months, the estimated 2-year survival rate was 89%. Therapy was discontinued in 24% of patients due to Grade III-IV toxicity. Frequent severe side effects that required dose reductions included neutropenia (49%), fatigue (43%), and neurologic toxicity (17%). The median PEG-IFN-alpha-2b and ara-C doses delivered were 3 mug/kg weekly and 7.5 mg daily, respectively, at 12 months of therapy. The activity and toxicity profiles of this combination was similar to those observed in historical patients treated with IFN-alpha and cytarabine. CONCLUSIONS. The combination of PEG-IFN-alpha-2b and ara-C is active but has significant toxicity in patients with chronic-phase CML at the dose schedule used. The recommended dose of PEG-IFN-alpha-2b in future combination studies is 3 mug/kg or less. (C) 2003 American Cancer Society.
引用
收藏
页码:3010 / 3016
页数:7
相关论文
共 21 条
[1]   A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia [J].
Baccarani, M ;
Rosti, G ;
de Vivo, A ;
Bonifazi, F ;
Russo, D ;
Martinelli, G ;
Testoni, N ;
Amabile, M ;
Fiacchini, M ;
Montefusco, E ;
Saglio, G ;
Tura, S .
BLOOD, 2002, 99 (05) :1527-1535
[2]  
Coiffier B, 2001, BLOOD, V98, p604A
[3]   GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia [J].
Cortes, J ;
Kantarjian, H ;
O'Brien, S ;
Kurzrock, R ;
Keating, M ;
Talpaz, M .
LEUKEMIA, 1998, 12 (06) :860-864
[4]   Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission [J].
Craddock, C ;
Szydio, RM ;
Klein, JP ;
Dazzi, F ;
Olavarria, E ;
van Rhee, F ;
Pocock, C ;
Cwynarski, K ;
Apperley, JF ;
Goldman, JM .
BLOOD, 2000, 96 (01) :86-90
[5]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[6]  
Gugliotta L, 2001, BLOOD, V98, p629A
[7]   Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia [J].
Guilhot, F ;
Chastang, C ;
Michallet, M ;
Guerci, A ;
Harousseau, JL ;
Maloisel, F ;
Bouabdallah, R ;
Guyotat, D ;
Cheron, N ;
Nicolini, F ;
Abgrall, JF ;
Tanzer, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :223-229
[8]   The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete problem list [J].
Hurst, JW ;
Morris, DC ;
Alexander, RW .
CLINICAL CARDIOLOGY, 1999, 22 (06) :385-390
[9]   Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].
Kantarjian, H ;
Sawyers, C ;
Hochhaus, A ;
Guilhot, F ;
Schiffer, C ;
Gambacorti-Passerini, C ;
Niederwieser, D ;
Resta, D ;
Capdeville, R ;
Zoellner, U ;
Talpaz, M ;
Druker, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652
[10]   Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine [J].
Kantarjian, HM ;
O'Brien, S ;
Smith, TL ;
Rios, MB ;
Cortes, J ;
Beran, M ;
Koller, C ;
Giles, FJ ;
Andreeff, M ;
Kornblau, S ;
Giralt, S ;
Keating, MJ ;
Talpaz, M .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :284-292